Telix Pharmaceuticals Receives ASX Waivers on Share Issuance Timing for Acquisition Consideration
MT Newswires Live
Sep 22
Telix Pharmaceuticals (ASX:TLX) sought waivers of an ASX rule to allow shares issued as upfront consideration and future consideration to be issued more than three months after its extraordinary general meeting, as the timing is contingent on completion of closing conditions and achievement of specific milestones, according to a Tuesday Australian bourse filing.
The company said ASX granted the waivers, with certain conditions, including that shares tied to the upfront payment are issued once the relevant deal conditions are met, and in any case no later than 12 months after shareholders approve the issue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.